NCT01848028 PsoBest - The German Psoriasis Registry
| NCT ID | NCT01848028 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2008-01 |
| Primary Completion | 2032-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 2008-01 with a primary completion date of 2032-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.
Eligibility Criteria
Inclusion Criteria: * patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist * age ≥ 18 years * being administered a specific systemic drug for the first time * informed consent to participate * sufficient language skills (German) Exclusion criteria: * lack of informed consent * patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)
Contact & Investigator
Matthias Augustin, Prof. Dr.
PRINCIPAL INVESTIGATOR
Universitätsklinikum Hamburg-Eppendorf
Frequently Asked Questions
Who can join the NCT01848028 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01848028 currently recruiting?
Yes, NCT01848028 is actively recruiting participants. Visit ClinicalTrials.gov or contact Universitätsklinikum Hamburg-Eppendorf to inquire about joining.
Where is the NCT01848028 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT01848028 clinical trial?
NCT01848028 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Matthias Augustin, Prof. Dr. at Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 3,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.